5 Best Day Trading Stocks to Buy Now

3. Dyne Therapeutics Inc. (NASDAQ:DYN)

Number of Hedge Fund Holdings: 61

Earlier this month, Dyne Therapeutics Inc. (NASDAQ:DYN) announced important updates for its DMD and DM1 programs. The firm revealed that it planned to submit an accelerated application for its DMD drug to target a launch in the first quarter of 2027. Dyne Therapeutics Inc. (NASDAQ:DYN) added that for DM1, it had completed enrollment for a Phase 1/2 trial. On March 8th, the firm revealed that it had started a Phase 3 trial of the drug DYNE-101 for the disease, and on the same day, Dyne Therapeutics Inc. (NASDAQ:DYN) revealed that its Phase 1/2 DELIVER trial for DMD had shown results when it came to baseline in lung function and other metrics.

Investment bank Morgan Stanley discussed the pharmaceutical company’s shares on March 3rd. It reduced the share price target to $47 from $50 and kept an Overweight rating, according to The Fly. Morgan Stanley outlined that Dyne Therapeutics Inc. (NASDAQ:DYN)’s programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) were on track, and 2026 could see the firm execute on its key programs.

Dyne Therapeutics Inc. (NASDAQ:DYN) is a biotechnology company focusing on developing treatments for neuromuscular diseases. It is headquartered in Waltham, Massachusetts.